Navelbine (Vinorelbine)

Vinorelbine is used in chemotherapy regimens targeting solid tumours and related disease pathways.

• Non‑small cell lung cancer: Improves disease control and may extend survival when used as part of standard chemotherapy regimens.
• Breast cancer: Contributes to tumour reduction and progression delay in combination therapy for advanced disease.
• Other solid tumours: Provides antineoplastic activity in a range of metastatic solid tumours when incorporated into multi‑agent protocols.

• Vinorelbine binds to the tubulin protein within cells, preventing microtubule polymerisation. This inhibition blocks the formation of the mitotic spindle, arresting cells in the M phase of the cell cycle and triggering apoptosis of rapidly dividing cancer cells.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: gastrointestinal upset common during treatment.
• Fatigue: persistent tiredness affecting daily activities.
• Constipation: decreased bowel motility.
• Alopecia: hair loss that may be temporary.
• Anemia: lowered red blood cell levels causing weakness.

Serious or Rare Side Effects

• Severe neutropenia with fever: may lead to life‑threatening infection.
• Pulmonary toxicity: cough, dyspnoea, or interstitial pneumonitis.
• Peripheral neuropathy: tingling or numbness in extremities.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythm requiring monitoring.
• Febrile neutropenia: high fever with low neutrophil count.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

• Monitor blood counts: perform regular CBC to detect neutropenia and anemia.
• Assess liver function: adjust dosing in hepatic impairment.
• Avoid in severe bone‑marrow suppression: contraindicated when baseline counts are critically low.
• Use antiemetics prophylactically: reduce nausea and vomiting incidence.
• Pregnancy safety: unknown; avoid use in pregnant women unless benefits outweigh risks.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Vinorelbine can interact with other medicines that affect its metabolism or bone‑marrow toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase vinorelbine exposure and toxicity.
• Concurrent myelosuppressive agents: can cause severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce vinorelbine effectiveness.
• QT‑prolonging drugs: increase risk of cardiac arrhythmias.
• Anticoagulants: may heighten bleeding tendency.
• Live vaccines: altered immune response; consider timing of administration.